glp-1 drugs pharmaceutical companies partnerships 2025 Market Size to Hit USD 212.73 Billion by 2035 Alarming rise in weight loss

Myth: Morning injections are more effective than evening ones Clinical data does not support this

However, GLP-1s can come with challenges, including gastrointestinal side effects, risk of micronutrient deficiencies, muscle and bone loss, poor long-term follow through with weight regain if stopped, and high costs

These drugs, derived from the hormone glucagon-like peptide-1, enhance insulin secretion, delay gastric emptying, reduce appetite, and promote weight loss [6]

For obesity alone, you must use FDA-approved Wegovy, not off-label diabetes drugs

Complex peptides like retatrutide have real manufacturing costs that cannot be circumvented without sacrificing quality

We only needed approval from the institutional review board' (Nair)